In the Zone

 

Aptinyx Inc.

 

In the Zone this week is Aptinyx Inc. in which trades on the Nasdaq Composite Index under stock symbol $APRX.

 

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. 

 

The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. 

 

It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment.

 

If you take a look at the stock chart of the company the stock has advanced fro a price low of $2.81 and is currently up 70.95% since then. Going forward what I am looking for is a breakout in price above Its June 2020 price high of $4.17 in order for this stock to advance higher to the upside.

 

Based on the stock chart of the company when looking at it from a technical standpoint what I would like to see in the days and weeks ahead is a advance in price above $1.65 in order for this stock to advance higher to the upside. 

At the close of the market on Friday the stock ended the day trading at $1.30 up $0.13 or 10.66% on heavier than average trading volume of 13.28 million. The average daily trading volume for the stock is 7.27 million. 

 

As we move ahead into the second trading week of the New Year please set you price alerts and keep this stock on your watch list for a potential advance in price above $1.65.

 

By Marlin Rolle

 

Please note that all the stocks listed are not buy recommendations; please do your own due diligence or get help from a professional before trading.